Optimization and Therapeutic Activity of Liposome-Conjugated Monoclonal Antibodies Against the ErbB family of Receptor Tyrosine Kinases: First Step in the Development of Therapeutic Antibody/Liposomal Anticancer Drug Combinations

Publisher： Bentham Science Publishers

E-ISSN： 1875-628x|3|10|704-713

ISSN： 1570-1808

Source： Letters in Drug Design & Discovery, Vol.3, Iss.10, 2006-12, pp. : 704-713

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparative Binding Analysis of Monoclonal Antibodies Against Native and Mutant Type in ErbB2 Receptor: A Theoretical Modeling Approach

By  

Current Pharmaceutical Biotechnology, Vol. 10, Iss. 7, 2009-11 ,pp. : 701-708

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic targeting of receptor tyrosine kinases in lung cancer

By Choong Nicholas W   Ma Patrick C   Salgia Ravi  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 3, 2005-06 ,pp. : 533-559

Informa Healthcare

Access to resources Recommend Favorite

Receptor Tyrosine Kinases as Therapeutic Targets the Model of the MET Oncogene

By  

Current Drug Targets, Vol. 2, Iss. 1, 2001-01 ,pp. : 41-55

Bentham Science Publishers

Access to resources Recommend Favorite

Receptor Tyrosine Kinases and Anticancer Therapy

By  

Current Pharmaceutical Design, Vol. 11, Iss. 9, 2005-04 ,pp. : 1139-1149

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic anticancer antibodies

By Murray Samuel   Linardou Helena  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 2, 2003-02 ,pp. : 177-222

Informa Healthcare

Access to resources Recommend Favorite